Predicting chemotherapy-induced menopause using baseline and post-chemotherapy anti-Müllerian hormone levels: Results of a pilot study.
Adolescent
Adult
Anti-Mullerian Hormone
/ blood
Antineoplastic Agents
/ adverse effects
Breast Neoplasms
/ blood
Female
Humans
Menopause, Premature
/ drug effects
Middle Aged
Pilot Projects
Primary Ovarian Insufficiency
/ blood
Prospective Studies
Quality of Life
Risk Assessment
/ methods
Young Adult
breast cancer
chemotherapy
chemotherapy-induced ovarian failure
Journal
Cancer reports (Hoboken, N.J.)
ISSN: 2573-8348
Titre abrégé: Cancer Rep (Hoboken)
Pays: United States
ID NLM: 101747728
Informations de publication
Date de publication:
06 2021
06 2021
Historique:
revised:
28
12
2020
received:
12
08
2020
accepted:
04
01
2021
pubmed:
5
3
2021
medline:
4
1
2022
entrez:
4
3
2021
Statut:
ppublish
Résumé
Chemotherapy can cause premature menopause which may result in adverse effects such as fertility loss, osteoporosis, cardiovascular disease and menopausal symptoms. It is thus very important that women are provided with accurate information regarding their risk of premature menopause as a consequence of proposed chemotherapy. Unfortunately, at present there are no reliable tools which can be applied in clinical practice to estimate the risk of premature menopause in women undergoing chemotherapy, beyond age of the patient and form of chemotherapy utilized. This was a pilot study to determine whether AMH levels pre and during chemotherapy are able to predict for chemotherapy induced menopause, and to assess quality of life and menopausal symptoms. Premenopausal women between 18 to 45 who were planned to undergo gonadotoxic chemotherapy with curative intent for either breast cancer or haematologic malignancy were recruited from a single centre. AMH, FSH, LH and oestradiol levels were recorded prior to commencement of therapy, during and following completion of chemotherapy. Menstrual status, menopausal symptoms and quality of life data were collected at baseline and during follow-up. Twenty two women were recruited. The baseline AMH was higher in women who regained menses post-chemotherapy (median 23.1 vs 9.9 pM (P = .06). Menopausal symptoms were significantly higher at 1 year post diagnosis than at baseline however quality of life was similar. AMH may be useful for predicting chemotherapy induced menopause. Further research is still required to determine the place of such testing for patient counselling and management.
Sections du résumé
BACKGROUND
Chemotherapy can cause premature menopause which may result in adverse effects such as fertility loss, osteoporosis, cardiovascular disease and menopausal symptoms. It is thus very important that women are provided with accurate information regarding their risk of premature menopause as a consequence of proposed chemotherapy. Unfortunately, at present there are no reliable tools which can be applied in clinical practice to estimate the risk of premature menopause in women undergoing chemotherapy, beyond age of the patient and form of chemotherapy utilized.
AIM
This was a pilot study to determine whether AMH levels pre and during chemotherapy are able to predict for chemotherapy induced menopause, and to assess quality of life and menopausal symptoms.
METHODS AND RESULTS
Premenopausal women between 18 to 45 who were planned to undergo gonadotoxic chemotherapy with curative intent for either breast cancer or haematologic malignancy were recruited from a single centre. AMH, FSH, LH and oestradiol levels were recorded prior to commencement of therapy, during and following completion of chemotherapy. Menstrual status, menopausal symptoms and quality of life data were collected at baseline and during follow-up. Twenty two women were recruited. The baseline AMH was higher in women who regained menses post-chemotherapy (median 23.1 vs 9.9 pM (P = .06). Menopausal symptoms were significantly higher at 1 year post diagnosis than at baseline however quality of life was similar.
CONCLUSION
AMH may be useful for predicting chemotherapy induced menopause. Further research is still required to determine the place of such testing for patient counselling and management.
Identifiants
pubmed: 33660428
doi: 10.1002/cnr2.1342
pmc: PMC8222560
doi:
Substances chimiques
Antineoplastic Agents
0
Anti-Mullerian Hormone
80497-65-0
Types de publication
Journal Article
Observational Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1342Informations de copyright
© 2021 The Authors. Cancer Reports published by Wiley Periodicals LLC.
Références
Cancer. 2010 May 1;116(9):2099-105
pubmed: 20187091
Fertil Steril. 2010 Jun;94(1):156-66
pubmed: 19342041
J Natl Cancer Inst. 1993 Mar 3;85(5):365-76
pubmed: 8433390
Cancer. 2007 Nov 15;110(10):2222-9
pubmed: 17932880
Hum Reprod. 2006 Oct;21(10):2583-92
pubmed: 16820385
Maturitas. 2010 Feb;65(2):161-6
pubmed: 19733988
Br J Cancer. 2007 Jun 18;96(12):1808-16
pubmed: 17533402
J Clin Endocrinol Metab. 2013 Feb;98(2):729-35
pubmed: 23316087
BMC Med. 2016 Oct 3;14(1):151
pubmed: 27716302
Cancer Rep (Hoboken). 2021 Jun;4(3):e1342
pubmed: 33660428
Cancer Invest. 2008 Apr-May;26(3):286-95
pubmed: 18317970
J Natl Cancer Inst. 2000 Jul 5;92(13):1054-64
pubmed: 10880548
N Engl J Med. 2018 Jul 12;379(2):122-137
pubmed: 29863451